Clinical trial Recruiting at 1 site Interventional Ages 65 to 99

Lower dose chemoradiotherapy for elderly patients with HPV-associated oropharynx cancer

Official title: Pilot Feasibility Trial of Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly (DACHOC-E)

Run by Baptist MD Anderson Cancer Center, Florida · NCT06309225 · Data updated 2026-11-12

This study is testing a lower dose of radiation and chemotherapy to see if it can help older patients with HPV-related throat cancer while causing fewer side effects than the usual higher doses.

Quick facts

Study typeInterventional
Ages65 Years to 99 Years
SexAll
Enrollment20 (estimated)
SponsorBaptist MD Anderson Cancer Center, Florida
Academic / other
Drugs / interventionsimmunotherapy, chemotherapy, radiation
Locations1 site (Jacksonville, Florida)
StatusRecruiting
StartedDecember 15, 2025
Main results expectedSeptember 30, 2027
Study endsSeptember 30, 2027
Registry record updatedSeptember 29, 2026
Trial IDNCT06309225 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are elderly patients aged 65 and older with a confirmed diagnosis of squamous cell carcinoma of the oropharynx who are P16-positive and have measurable disease.

Probably not a fit

Patients with metastatic disease, recurrent cancer, or those who have received prior radiation therapy for other malignancies may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of a modified regimen of lower dose radiation therapy and chemotherapy in elderly patients diagnosed with HPV-associated oropharynx cancer. Participants will receive radiation therapy once daily for five weeks, totaling 55 Gy, along with weekly cisplatin chemotherapy. The goal is to compare the outcomes of this less intensive treatment approach to standard higher dose regimens, focusing on both efficacy and side effects. By evaluating the results, researchers aim to determine if this new approach can maintain similar survival rates while reducing treatment-related complications.

Why it matters

Potential benefit: If successful, this study could lead to a safer treatment option for elderly patients with oropharynx cancer, minimizing side effects while maintaining effective cancer control.

How similar studies have gone: Previous studies have indicated that lower dose radiation can achieve comparable cancer control rates with fewer side effects, suggesting potential success for this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pathologically proven diagnosis of squamous cell carcinoma of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls)
* Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations.
* P16-positive based on local site immunohistochemical tissue staining
* Clinical stage T1-3, N1-2, M0 (AJCC, 8th ed.)
* Age ≥ 65.
* Normal organ and marrow function within 14 days prior to registration defined as follows:
* Absolute neutrophil count ≥ 1,500/mcL
* Platelets ≥ 100,000/mcL
* Hemoglobin ≥ 8.0 g/dL
* Total bilirubin ≤ 1.5× institutional upper limit of normal (ULN)
* AST(SGOT) or ALT(SGPT) ≤ 3.0 × institutional ULN
* Serum creatinine ≤ 1.5× ULN

Exclusion Criteria:

* Metastatic disease
* Recurrent disease after primary management Cancers with center of mass is outside the oropharyngeal boundaries
* Synchronous double primaries
* Prior radiotherapy for lymphoma or other malignancy
* Prior systemic therapy including immunotherapy
* Severe active comorbidity where life expectancy is \<1 year.
* Autoimmune disease
* Uncontrolled HIV

Where it's running

  • Baptist MD Anderson Cancer Center
    Jacksonville, Florida, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.